candidemia – Page 2

Candida blankii: The Difficult Capture of a Fungus With Pathogenic Potential

mycolabadmin

Candida blankii is a rare fungal pathogen that is increasingly being found in hospital patients’ bloodstreams and respiratory tracts. The organism is difficult to identify using standard laboratory tests, which can delay diagnosis and treatment. This case report describes two adult patients with C. blankii infections and highlights the challenges in identifying this emerging pathogen and its resistance to common antifungal medications.

Fungal Infections – a Stealthy Enemy in Patients with Chronic Granulomatous Disease: a 28-years’ Experience from North India

mycolabadmin

Patients with chronic granulomatous disease (CGD), a rare immune system disorder, are highly susceptible to serious fungal infections. This study of 99 patients over 28 years found that 40% developed fungal infections, mostly caused by Aspergillus fungi affecting the lungs. These infections were life-threatening, with over half the infected patients dying despite aggressive treatment with antifungal medications. Doctors need to screen for fungal infections early, even in patients without obvious symptoms, and treat infants and males more aggressively.

Cracks in the Curriculum: The Hidden Deficiencies in Fungal Disease Coverage in Medical Books

mycolabadmin

This study examined how well major medical textbooks cover fungal diseases, which kill millions of people annually. Researchers found that books focused on infectious diseases had much better information about fungal infections than general internal medicine textbooks. Most textbooks failed to adequately cover how to prevent fungal infections and diagnose them correctly, which could lead to delayed treatment and worse patient outcomes.

Molecular Identification of Candida Species among Iranian Patients: Pursuing Candida auris

mycolabadmin

Researchers in Iran studied 136 hospital patients to identify different types of Candida fungal infections using a molecular laboratory technique called PCR-RFLP. They found that while Candida albicans remained the most common species, other Candida species were increasingly prevalent in hospitalized patients. The study developed a cost-effective diagnostic method that could help developing countries identify these fungal infections faster and more accurately, though the dangerous multidrug-resistant Candida auris was not found in their samples.

Impact of Clove Oil on Biofilm Formation in Candida albicans and Its Effects on Mice with Candida Vaginitis

mycolabadmin

Clove oil, a common kitchen spice, shows promise as a treatment for vaginal yeast infections caused by Candida albicans. The oil contains eugenol, which blocks the fungus’s ability to form protective biofilms and reduces inflammation. In mouse studies, clove oil treatment decreased yeast infection symptoms and lowered inflammatory markers, suggesting it could be a safe, natural alternative to conventional antifungal drugs.

Antifungal persistence: Clinical relevance and mechanisms

mycolabadmin

Some fungal infections don’t respond well to antifungal medications even though the fungi aren’t drug-resistant. This happens because a small percentage of fungal cells enter a dormant, low-energy state that protects them from being killed by the drugs. Understanding how these persistent cells survive and finding ways to target them could help prevent recurring fungal infections and improve treatment outcomes.

Molecular Identification of Candida Species among Iranian Patients: Pursuing Candida auris

mycolabadmin

This study evaluated a simple molecular test called PCR-RFLP to identify different types of Candida fungi in hospitalized patients in Iran. Among 136 patient samples, researchers found eight different Candida species, with common Candida albicans being most prevalent, but other more dangerous species also present. No cases of the emerging pathogen Candida auris were found, though the test method can effectively detect it. The researchers conclude this cost-effective test could be valuable for identifying dangerous fungal infections in developing countries.

John Perfect Shares Insights on Infectious Diseases, Antifungal Therapy, and Drug Resistance

mycolabadmin

This interview with Dr. John Perfect, a leading expert in fungal infections, discusses how antifungal treatments have evolved over his 48-year career. He explains that while fungal resistance is a concern, it’s less problematic than bacterial antibiotic resistance because fungi don’t spread resistance through plasmids. Dr. Perfect emphasizes the importance of newer, faster-acting antifungal drugs and combining drug therapy with immune system support to better treat serious fungal infections like cryptococcal meningitis and candidemia.

Toward the consensus of definitions for the phenomena of antifungal tolerance and persistence in filamentous fungi

mycolabadmin

Scientists have proposed clear definitions and testing methods for two drug-resistance phenomena in fungi that cause infections. Unlike typical drug resistance, tolerance and persistence allow fungi to survive antifungal medications but in different ways: tolerance affects most spores while persistence affects only a small fraction. By standardizing how these phenomena are tested using fungal spores and measuring how quickly drugs kill them, researchers can better understand treatment failures and develop better therapies.

John Perfect Shares Insights on Infectious Diseases, Antifungal Therapy, and Drug Resistance

mycolabadmin

Dr. John Perfect, a leading expert in fungal infections, shares his 48 years of experience studying infectious diseases, particularly focusing on Cryptococcus and candida infections. He discusses how antifungal medications have evolved from highly toxic drugs to more effective treatments, while emphasizing the need for faster-acting drugs that require shorter treatment periods. The interview covers emerging diagnostic tools using molecular methods, the promise of combining drugs with immune-boosting therapies, and the importance of understanding how fungi survive in the human body to develop better treatments.

Disease: candidemia